Business Context and Reporting Period
This Form 8-K Current Report was filed by Relmada Therapeutics, Inc. on December 8, 2021, with the report date reflecting the earliest event reported on that same day. The filing details the entry into a material definitive agreement regarding an underwritten public offering of the Company's common stock.
Key Financial Metrics
- Offering Size: 8,823,530 shares of common stock initially offered, with an additional 1,323,529 shares purchased via the full exercise of the underwriters' option.
- Offering Price: $17.00 per share to the public; $15.98 per share to underwriters.
- Net Proceeds: Approximately $161.6 million (including proceeds from the option exercise).
- Closing Date: December 13, 2021.
- Underwriters: Goldman Sachs & Co. LLC and Jefferies LLC.
Material Changes
The primary material change reported is the execution of an underwriting agreement and the subsequent closing of a significant equity financing. This transaction represents a substantial increase in the Company's cash liquidity compared to the pre-offering period. The filing does not provide comparative financial metrics (such as revenue or profit) for prior periods as this is a current report focused on a specific corporate event rather than a periodic financial statement.
Outlook, Risks, and Contingencies
The Company utilized the proceeds from this offering to fund its operations and clinical development programs, though specific allocation details are not provided in this text. The Underwriting Agreement includes customary indemnification provisions where the Company agreed to indemnify the Underwriters against certain liabilities under the Securities Act of 1933. The filing incorporates the full text of the Underwriting Agreement by reference for complete terms.
Investor Verification Checklist
- Verify the final closing date of December 13, 2021, and confirm the total number of shares issued (10,147,059 total).
- Confirm the exact net proceeds of $161.6 million after deducting underwriting discounts and commissions.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific lock-up periods or other restrictive covenants not detailed in the summary.
- Check subsequent filings to determine how the raised capital is being allocated across clinical trials and operational expenses.